ResMed : PAP-linked Survival Rate, New COPD Prevalence, Benefits of Telemonitoring Ventilation Patients among 14 ResMed-supported Abstracts at ERS 2021

What's happening

ResMed, a global leader in sleep and respiratory care research and digitally
connected solutions, is presenting 14 abstracts at the European Respiratory Society (ERS) International Congress 2021. Three of note listed below:

When: September 6-8, 2021

Study #1: The health and cost benefits of telemonitoring patients on home mechanical ventilation

• Time: Monday 6 September, 13:15-14:15 CET (8:15-9:15 a.m. in Brazil)
• Presenter: Claudia Albertini, ResMed, Head of Clinical Marketing, LATAM
• Find the abstract: 'Clinical and economic benefits of HMV telemonitoring in Brazil' (Session 249)
• Contact: [e-mail];
  [e-mail]

Study #2: How many Europeans have chronic obstructive pulmonary disease (COPD) in 2020 - and may in 2050

• Time: Tuesday 7 September, 09:30-11:00 CET
• Presenter: Adam Benjafield, ResMed, vice president of Medical Affairs
• Find the abstract: 'An estimate of the European prevalence of COPD in 2050' (Session 328)
• Contact: Jayme Rubenstein, +1 858.836.6798, [e-mail]

Study #3: (late-breaking abstract): Do people with sleep apnea live longer when adherent on PAP?

• Time: Wednesday 8 September, 11:15-12:45 CET
• Presenter: Jean-Louis Pepin, Grenoble Alpes University, Grenoble, France
• Find the abstract: 'CPAP termination and all-cause mortality: a French nationwide database
  analysis' (Session 494)
• Contact: Jayme Rubenstein, +1 858.836.6798, [e-mail]

For additional information about ResMed and its ERS abstracts, please email [e-mail].

# # #